Success rate of current human-derived gastric cancer organoids establishment and influencing factors: A systematic review and meta-analysis

Table 1 The clinical characteristic of gastric cancer organoids

Ref.	Location	Molecular subtype	Histologic classification	Differentiation	pTNM stage	Source
Yan et al[21]	Body, fundus, cardia, antrum	EBV, MSI, Mixed	Intestinal, diffuse, mixed mucinous, mixed	Moderate, poor	IA-IIIC	Surgery
Kawasaki et al[22]	NM	NM	NET, NEC	NM	NM	Surgery, biopsy
Nanki et al[23]	GEJ, corpus, antrum	MSI, CIN, GS, MSS	Intestinal, diffuse, mixed	NM	IA-IV	Surgery, biopsy, ascites puncture
Steele et al[24]	Fundus	NM	Intestinal, diffuse, signet-ring cell	Poorly differentiated	NM	Surgery
Li et al[25]	Antrum, cardia, body	NM	Intestinal, diffuse, mixed	Poor, moderate, high	IA-IV	Surgery
Zou et al[26]	NM	NM	Intestinal, mixed, SRCC	Poor, moderate	IIB-IVA	Surgery, biopsy
Li et al[27]	Antrum, corpus, cardia	NM	NM	Poor, signet-ring cell, middle	NM	Biopsy
Togasaki et al[28]	NM	GS, CIN	Diffuse	Poor, sig, muc	IIA-IV	Surgery, ascites, biopsy, autopsy
Xiao et al[29]	NM	MSI, HER2, EBV	Adenocarcinoma	Moderate to poor differentiation	III	Surgery
Seidlitz et al[30]	NM	NM	Intestinal, diffuse, mixed	NM	IIA-IV	Surgery
Gao et al[31]	NM	NM	Adenocarcinoma	NM	NM	Surgery, biopsy
Bartfeld et al[32]	Corpus	NM	NM	NM	NM	Surgery
Wang et al[33]	Cardia, corpus	NM	SCRR	Poorly differentiated	IIB-III	Biopsy
Kumar et al[34]	Antrum, distal, corpus, pylorus, cardia, proximal, peritoneum	GS, MSI, CIN	Intestinal, diffuse, mixed	NM	I-IV	Biopsy
Harada et al[35]	NM	NM	Por, tub1, tub2, muc	Differentiated, undifferentiated	IA-IIIC	Surgery
Ukai et al[36]	NM	NM	Intestinal, diffuse, tub1, tub2, muc, pap	Por	IA-IIIC	Surgery
Tong et al[37]	NM	MSS, MSI	Intestinal	NM	NM	NM
Yamaguchi et al[38]	Corpus, antrum	NM	NM	NM	NM	Surgery or ESD

pTNM: Pathological tumor-node-metastasis; NM: Not mentioned; ESD: Endoscopic submucosal dissection; NET: Neuroendocrine tumor; NEC: Neuroendocrine carcinoma; EBV: Epstein-Barr virus; CIN: Chromosomal instability; GS: Genomically stable; MSS: Microsatellite stable; MSI: Microsatellite instable; SRCC: Signet-ring cell cancer; GEJ: Gastroesophagus junction; HER2: Human epidermal growth factor receptor 2.